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We investigated the association between thymidylate synthase (TS) germline polymorphisms and response to 5-fluorouracil-based
chemotherapy in 80 patients with liver-only metastatic colorectal cancer (MCRC). The tandem repeat polymorphism (VNTR) in
TS 50-untranslated region (50-UTR), which consists of two (2R) or three (3R) 28-bp repeated sequences, with or without a G/C
nucleotide change in 3R carriers (3G or 3C) and a 6-bp insertion/deletion (6þ/6 ) in the TS 30-UTR, was studied. The distinction
between high (2R/3G, 3C/3G and 3G/3G) and low (2R/2R, 2R/3C and 3C/3C) TS expression genotypes according to the 50-UTR
VNTRþG/C nucleotide change showed significant association with tumour response (P¼0.01). In particular, high TS expression
genotypes were found in 8 out of 34 patients (23.5%) with complete or partial response and in 24 out of 46 patients (52%) with
stable disease and disease progression. Liver-only MCRC patients are a homogeneous and clinical relevant subgroup that may
represent an ideal setting for studying the actual influence of TS polymorphisms.
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Functional polymorphisms in the 50-untranslated region (50-UTR)
and the 30-UTR of the thymidylate synthase (TS) gene have been
identified in the last decade (Marsh, 2005). A variable number of
28-bp tandem repeated sequence (VNTR) in TS 50-UTR determines
two (2R) or three (3R) alleles (Horie et al, 1995) and three common
genotypes (2R/2R, 2R/3R and 3R/3R). Upregulated TS protein
levels were found to be associated with the 3R allele (Kawakami
et al, 1999; Yu et al, 2008). A G/C single-nucleotide polymorphism
(SNP) in the 3R allele was found to determine two additional alleles
(3G or 3C) at this locus (Kawakami and Watanabe, 2003; Mandola
et al, 2003), and according to their functional role, it allows
a distinction between high (2R/3G, 3C/3G and 3G/3G) and low (2R/
2R, 2R/3C and 3C/3C) TS expression genotypes in vivo (Morganti
et al, 2005; Yawata et al, 2005). A more recently discovered TS
genetic variant is a 6-bp insertion/deletion (6þ/6)i n3 0-UTR
(Ulrich et al, 2000). TS 30-UTR genotypes (6þ/6þ , 6þ/6  and
6 /6 ) seem to be associated with variable TS mRNA levels
(Mandola et al, 2004); however, the functional effect of the 30-UTR
polymorphism is not well defined yet (Calascibetta et al, 2004).
5-Fluorouracil is a fundamental drug in the treatment of patients
with colorectal cancer, and TS levels are considered an important
factor for explaining the differences in 5-fluorouracil antitumour
activity (Popat et al, 2004). Therefore, the TS functional
polymorphisms are under investigation for the possibility of
optimising chemotherapy (Yong and Innocenti, 2007). Studies in
patients with metastatic colorectal cancer showed that carriers of
the TS 50-UTR 3R (3G) and/or the TS 30-UTR 6þ alleles had
adverse clinical outcomes (Pullarkat et al, 2001; Etienne et al, 2002;
Park et al, 2002; Marcuello et al, 2004; Stoehlmacher et al, 2004;
Martinez-Balibrea et al, 2007); however, such an association was
not always detected (Lecomte et al, 2004; Jakobsen et al, 2005;
Ruzzo et al, 2007a,b). Heterogeneity in clinical experimental
conditions (Sorbye et al, 2007), in tumour burden (Ko ¨hne et al,
2002) and in genetic/molecular features in the presence of a
multisite metastatic disease (Yokota, 2000) may explain variable
results in these pharmacogenetic studies.
We hypothesised that the 20–30% of patients with liver-only
metastatic colorectal cancer (MCRC) (Mandala ` et al, 2007) may
represent a favourably homogeneous and clinically relevant setting
for evaluating the role of TS polymorphisms for predicting
response to 5-fluorouracil-based chemotherapy. For this purpose,
we performed an analysis of TS polymorphisms in patients with
liver-only MCRC who were previously enrolled in two prospective
pharmacogenetic studies including 312 patients treated with
first-line FOLFOX (bolus/infusional 5-fluorouracil coupled with
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soxaliplatin) or FOLFIRI (bolus/infusional 5-fluorouracil coupled
with irinotecan) regimens (Ruzzo et al, 2007a,b). FOLFOX and
FOLFIRI regimens are equally active and they produce comparable
response rates in first-line chemotherapy. In both the regimens,
5-fluorouracil is used at the same dose and schedule (Colucci et al,
2005). The primary end point of the study was the association
between TS polymorphism and tumour response.
MATERIALS AND METHODS
Study population
Three hundred and twelve patients with metastatic colorectal
cancer were prospectively enrolled in two previous pharmaco-
genetic studies (Ruzzo et al, 2007a,b) and they underwent first-line
chemotherapy including leucovorin 100mgm
 2 administered
as a 2-h infusion before 5-fluorouracil 400mgm
 2 administered
as an intravenous bolus injection and 5-fluorouracil 600mgm
 2 as
a 22-h infusion immediately after FU bolus injection on days 1 and
2, every 2 weeks. Eighty patients (25.6%) had liver-only metastatic
disease and they were included in this analysis. Ten of the
80 patients had history of liver surgery for metastasectomy and
they were with liver-only relapse.
The 80 studied patients had cytologically or histologically
confirmed metastatic colorectal cancer and the presence of at
least one measurable lesion. Pretreatment evaluation included a
complete medical and clinical–physical examination, KPS evalua-
tion, baseline measurement of tumour size based on CT scan,
serum chemistries and CEA. Objective response was evaluated
after four cycles of treatment and then every 2 months according
to the RECIST criteria (Therasse et al, 2000). For the purpose of
this study, radiology studies of the 80 patients were reviewed for
confirming the treatment outcomes. Patients’ characteristics and
their outcomes were unknown to investigators performing genetic
analyses. The study was approved by local ethical committees and
patients provided signed informed consent.
Analysis of polymorphisms
A blood sample from each enrolled patient was used for
genotyping and it was collected before starting chemotherapy.
Genomic DNA was extracted from 200ml whole blood using the
QiaAmp kit (Qiagen, Valencia, CA, USA). All polymorphisms were
investigated using a PCR-restriction fragment length polymor-
phism technique. The assays for studying polymorphisms were
performed as described previously (Ruzzo et al, 2007a,b).
Statistical analyses
The primary end point of the study was the association between TS
polymorphisms in patients with liver-only MCRC and response to
5-fluorouracil-based chemotherapy. Genotype frequencies were
checked for agreement with those expected under the Hardy–
Weinberg equilibrium. Genotypes for each polymorphism were
analysed as three-group categorical variable in a codominant
model and they were also grouped according to the recessive and
additive model. Patients were categorised as responders (patients
with complete or partial response) and non-responders (patients
with stable disease or disease progression). The w
2-test was used
for comparing proportions. Statistical significance was defined as
Po0.05. A Bonferroni correction of the P-value for multiple
comparisons was used where applicable.
The SHEsis software platform (http://202.120.7.14/analysis/
myAnalysis.php) was used to estimate haplotype frequencies and
the presence of linkage disequilibrium (LD). Linkage disequili-
brium exists between two SNPs, if their variants appear together
more often than expected (non-random inheritance). Linkage
disequilibrium was estimated using r
2, with r
2¼1 indicating
complete LD and r
2¼0 indicating absent LD. Haplotype
frequencies were reconstructed in the study population of
responders and non-responders. Association of haplotypes with
clinical outcome was estimated by comparing haplotype distribu-
tions among dichotomised patients using the w
2-test.
RESULTS
The characteristics of the 80 studied patients and the overall
frequencies of genotypes are shown in Table 1. All patients were
assessable for response and they received a minimum of four
cycles of chemotherapy. In the 80 patients, there was one complete
response (1.2%), 33 partial responses (41.2%), 30 stable diseases
(37.6%) and 16 progressions (20%). Median age was 63 years
(minimum 38 years and maximum 75 years). Liver metastases
were synchronous in 22 patients (27.5%) and metachronous in
68 patients (72.5%). The frequencies of genotypes are in Hardy–
Weinberg equilibrium and they are consistent with those observed
in Caucasian ethnicity (Archive of Genetic Association Studies
accessible at: http://geneticassociationdb.nih.gov/).
No significant association between clinicopathological features
and tumour response was found (Table 2). The analysis of the
three polymorphisms and response is shown in Table 3. The
Bonferroni-adjusted P-value for the three comparisons is 0.05/3,
P¼0.016. The TS 50-UTR VNTR with G/C polymorphism in 3R
alleles showed association with treatment outcome (P¼0.011). In
particular, high TS expression genotypes (2R/3G, 3C/3G and
Table 1 Characteristics of the 80 patients and genotype frequencies
No. of patients (%)
Sex
Male 48 (60)
Female 32 (40)
Karnofsky performance status
90–100 58 (72)
80 22 (28)
Resected primary tumour
Yes 70 (87)
No 10 (13)
Prior adjuvant therapy
None 44 (55)
Yes 36 (45)
Carcinoembryonic antigen
p10ngml
 1 56 (70)
410ngml
 1 24 (30)
Genotypes
TS 50-UTR VNTR
a
2R/2R 16 (20)
2R/3R 38 (47)
3R/3R 26 (33)
TS 50-UTR VNTR+G/C
b
2R/2R, 2R/3C, 3C/3C 48 (60)
2R/3G, 3C/3G, 3G/3G 32 (40)
TS 30-UTR
 6/ 6 30 (38)
 6/+6 40 (50)
+6/+6 10 (12)
aThe variable number of tandem repeats (VNTR) polymorphism is a two (2R)o r
three (3R) 28-bp tandem repeat sequence in TS 50-UTR.
bA single-nucleotide change
in 3R allele is a second polymorphism that distinguishes 3G carriers (2R/3G, 3G/3G
and 3G/3C genotypes) from non-3G carriers (2R/2R, 2R/3C and 3C/3C genotypes).
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s3G/3G) were found in 8 out of 34 patients with complete or partial
response (23.5%) and 24 out of 46 patients with stable disease and
disease progression (52%). The 50-UTR VNTR and the 30-UTR
6-bp insertion/deletion (6þ/6 ) did not show association with
tumour response. To further evaluate these two variants, their
distribution was explored in recessive and additive models also,
but without finding significant associations (Table 4).
The TS 50-UTR and TS 30-UTR loci showed mild LD (r
2¼0.17).
As shown in Table 5, non-3G haplotypes were prevalent in
responders and 3G haplotypes in non-responders, with signifi-
cantly different distribution of the 3G/6  haplotype.
Eleven responsive patients underwent liver surgery for resection
of the residual metastatic disease (13.7%). Clear resection margins
with removal of all known metastatic lesions were attained in these
patients, with 10 of them carrying one of the low TS expression
genotypes (2R/2R, 2R/3C and 3C/3C). At the time of data analysis
(March 2008), 78 patients suffered from disease progression
(97.5%). For addressing an exploratory analysis of time to
progression in patients with high and low TS expression
genotypes, time to event distributions were studied using the
Kaplan–Meier method. As shown in Figure 1, the results support
the influence of the TS 50-UTR VNTR with G/C SNP on the
outcome of these patients.
DISCUSSION
To the best of our knowledge, this is the first analysis of TS
polymorphisms in patients with liver-only MCRC. In comparison
with previous studies (Pullarkat et al, 2001; Etienne et al, 2002;
Table 2 Characteristics of the patients and tumour response
No. of patients (%)
Characteristics No. of patients (%) Responders
a (N¼34) Non-responders
a (N¼46) P-value
Karnofsky performance status
90–100 58 (72) 26 (76) 32 (70) 0.6
80 22 (28) 8 (24) 14 (30)
Resected primary tumour
Yes 67 (84) 30 (88) 37 (80) 0.5
No 13 (16) 4 (12) 9 (20)
Prior adjuvant therapy
None 44 (55) 21 (62) 23 (50) 0.4
Yes 36 (45) 13 (38) 23 (50)
Carcinoembryonic antigen
p10ngml
 1 56 (70) 26 (76) 30 (65) 0.4
410ngml
 1 24 (30) 8 (24) 16 (35)
aResponders are patients with complete or partial response. Non-responders are patients with stable disease or disease progression.
Table 3 Association between genotypes and response to chemotherapy
in the 80 patients
No. of patients (%)
Genotypes
No. of
patients (%)
Responders
a
(N¼34)
Non-responders
a
(N¼46) P-value
TS 50-UTR
2R/2R 16 (20) 10 (30) 6 (13)
2R/3R 38 (47) 14 (40) 24 (52) 0.19
3R/3R 26 (33) 10 (30) 16 (35)
TS 50-UTR
b
2R/2R, 2R/
3C, 3C/3C
48 (60) 26 (76) 22 (48) 0.011
y
2R/3G, 3C/
3G, 3G/3G
32 (40) 8 (24) 24 (52)
TS 30-UTR
 6/ 6 30 (38) 11 (32) 19 (41)
 6/+6 40 (50) 20 (59) 20 (44) 0.37
+6/+6 10 (12) 3 (9) 7 (15)
aResponders are patients with complete or partial response. Non-Responders are
patients with stable disease or disease progression.
bAnalysis of the TS 50-UTR VNTR
with C/G nucleotide change in 3R allele carriers. Low-expression genotypes are 2R/
2R, 2R/3C and 3C/3C. High-expression genotypes are 2R/3G, 3G/3G and 3G/3C.
yPo0.016 is the level of significance according to the Bonferroni adjustment for three
comparisons.
Table 4 Association between genotypes and response to chemotherapy
in additive and recessive models
No. of patients (%)
Genotypes
No. of
patients (%)
Responders
a
(N¼34)
Non-responders
a
(N¼46) P-value
TS 50-UTR
Recessive model
2R/2R, 2R/3R 54 (67) 24 (70) 30 (65) 0.63
3R/3R 26 (33) 10 (30) 16 (35)
TS 50-UTR
Additive model
2R/2R 16 (20) 10 (30) 6 (13) 0.09
2R/3R, 3R/3R 64 (80) 24 (70) 40 (87)
TS 30-UTR
Recessive model
 6/ 6,
 6/+6
70 (87) 31 (91) 39 (85) 0.50
+6/+6 10 (13) 3 (9) 7 (15)
TS 30-UTR
Additive model
 6/ 6 30 (38) 11 (32) 19 (41) 0.48
 6/+6,
+6+6
50 (62) 23 (68) 27 (59)
aResponders are patients with complete or partial response. Non-responders are
patients with stable disease or disease progression.
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sPark et al, 2002; Lecomte et al, 2004; Marcuello et al, 2004;
Stoehlmacher et al, 2004; Jakobsen et al, 2005; Martinez-Balibrea
et al, 2007; Ruzzo et al, 2007a,b), we evaluated a homogeneous and
low-burden disease population that was exposed to the same
regimen of 5-fluorouracil including both bolus and infusional
administration of the drug (Hoshino et al, 2005).
Heterogeneity in clinical features in patients with metastatic
disease (Sorbye et al, 2007) may represent a major limitation for
observing actual pharmacogenetic effects of functional germline
polymorphisms. Notably, the number of metastatic sites plays a
relevant prognostic role in patients with metastatic colorectal
cancer (Ko ¨hne et al, 2002), and differences in clinical outcomes
can be observed between patients with different metastatic sites
(Ko ¨hne et al, 2002). The planning of this study was also motivated
by the fact that colorectal cancer commonly metastasises to the
liver, and such a single-organ involvement, instead of a multisite
metastatic disease, can accurately be monitored during chemo-
therapy for the assessment of response (Trillet-Lenoir et al, 2002).
Low-burden metastatic disease may also limit the impact of
heterogeneity in molecular/genetic alterations as they accumulate
during tumour progression and metastatisation (Yokota, 2000).
Loss of heterozygosity (LOH) is to be included among these
possible genetic changes. Owing to LOH at the TS locus on
chromosome 18 in cancer cells, carriers of the germline hetero-
zygous 2R/3R genotype can acquire the 2R/loss genotype in their
tumours (Kawakami et al, 2002; Uchida et al, 2004a,b). Therefore,
the lower responsiveness of germline 2R/3R carriers could not be
displayed because heterozygous patients with tumour 2R/loss
genotype behave as 2R/2R patients (Uchida et al, 2004a,b). This
phenomenon implies that responsiveness to 5-fluorouracil-based
therapy may depend on the tumour rather than on the germline
status of the genotypes (Uchida et al, 2004a,b). However, our
findings suggest that the double assessment of the VNTR plus G/C
nucleotide change with dichotomisation of patients into carriers of
high (2R/3G, 3C/3G and 3G/3G) and low (2R/2R, 2R/3C and 3C/3C)
TS expression genotypes may not suffer from the possible presence
of LOH. The finding of the association between TS 50-UTR
VNTRþG/C and tumour response may not only reflect a better
functional characterisation of 3C and 3G alleles, but also a less
extensive influence of tumour LOH on the germline assessment for
high-TS expression genotypes (2R/3G, 3C/3G and 3G/3G).
In our opinion, TS polymorphisms deserved the present
investigation more than other genetic variants with putative
influence on 5-fluorouracil activity (i.e. methylenetetrahydrofolate
reductase gene polymorphisms). In addition to the fact that TS is
the target enzyme of 5-fluorouracil, it has been observed that TS
levels may be dynamic, with upregulation after fluoropyrimidine
exposure (Uchida et al, 2004a,b; Mauritz et al, 2007). In particular,
this effect was described in liver metastases from colorectal cancer
in patients who received bolus 5-fluorouracil (Mauritz et al, 2007).
Therefore, TS polymorphisms may influence the outcome to
5-fluorouracil chemotherapy, not only for their role in determining
different baseline levels of TS activity (Marsh, 2005), but also
for modulating the enhancement of TS levels in response to
5-fluorouracil. In fact, the 5-fluorouracil-induced upregulation of
TS mRNA may be greater in carriers of high-expression TS
genotypes than in carriers of low-expression TS genotypes. We
cannot rule out, however, that a double assessment of TS and
methylenetetrahydrofolate reductase polymorphisms may improve
the predictive role of the single analysis of TS polymorphisms.
Another reason for studying pharmacogenetics in liver-only
MCRC patients is related to the lack of predictive factor for
response to neoadjuvant chemotherapy. Liver surgery can provide
long-term survival for liver-only, metastatic colorectal cancer
patients, but liver metastasectomy is feasible in only 15–25% of
the patients. Neoadjuvant chemotherapy can provide response
rates as high as 50%, allowing liver metastasectomy in about
10–15% of patients initially deemed unresectable. Tumour
response to preoperative chemotherapy seems to be associated
with outcome following liver resection for colorectal metastases
(Folprecht et al, 2005) and, if genetically predictable, it could be
improved by the selective choice of available drugs. In this study,
10 of the 11 responsive patients who underwent liver surgery were
carriers of low TS expression genotypes (2R/2R, 2R/3C and 3C/3C).
Actually, we performed an analysis of TS polymorphisms for
response to 5-fluorouracil and we did not address this study to
pharmacogenetics for liver metastases resectability and survival
after preoperative chemotherapy. These end points require a
prospective study, including a baseline multidisciplinary evalua-
tion of the unresectable liver disease and long-term follow-up.
In conclusion, the homogeneous subgroup of patients with
liver-only metastatic disease allowed the predictive role of TS
polymorphisms to stand out. In fact, the association between
polymorphisms and tumour response was included in the
secondary end points of our two previous pharmacogenetic studies
(Ruzzo et al, 2007a,b), but these analyses failed to demonstrate a
predictive role for the genetic variants. The clinical setting assumes
a relevant role for exploring the pharmacogenetic associations in
patients with metastatic cancer and additional studies are
warranted for confirming our findings.
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Table 5 Distribution of estimated haplotype frequencies according to
treatment outcome
Haplotype Non-responders (%) Responders (%) v
2
2R/6  7.3 9.7 0.3
2R/6+ 32.5 41.3 0.06
3C/6  8.9 9.6 0.7
3C/6+ 16.3 19.9 0.2
3G/6  26.2 16.9 0.01
3G/6+ 6.2 5.2 0.5
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Figure 1 Kaplan–Meier analysis of time to progression (TTP) in patients
with low TS expression genotypes (2R/2R, 2R/3C and 3C/3C) and high TS
expression genotypes (2R/3G, 3C/3G and 3G/3G). TTP was calculated from
the start of chemotherapy to the first evidence of disease progression. Two
patients who underwent resection of liver metastases were progression-
free at the time of analysis (one with a low TS expression genotype and the
other with a high TS expression genotype). w
2 of the log-rank test¼10.4
(P¼0.001).
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